Exploring how DNA modifications affect telomeres in cancer cells
Understanding the impact of DNA ADP-ribosylation on telomere function in cancer cells
This study is looking at how a specific change in DNA affects the protective ends of chromosomes, called telomeres, which help cancer cells live longer, and it hopes to find new ways to treat cancers that rely on this process, especially for patients with certain types of cancer.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10893378 on NIH RePORTER |
What this research studies
This research investigates the role of DNA ADP-ribosylation in the functioning of telomeres, which are crucial for the longevity of cancer cells. By understanding how this modification impacts telomere maintenance, the study aims to identify new therapeutic targets for cancer treatment. The approach involves disrupting specific enzymes that regulate ADP-ribosylation, potentially leading to improved cancer therapies. Patients with cancers that utilize Alternative Lengthening of Telomeres (ALT) may particularly benefit from these insights.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that rely on Alternative Lengthening of Telomeres (ALT) for their growth and survival.
Not a fit: Patients whose cancers do not utilize the ALT mechanism may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for certain types of cancer by targeting telomere maintenance mechanisms.
How similar studies have performed: Previous research has shown promising results in targeting ADP-ribosylation for cancer therapy, indicating that this approach may be effective.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Wondisford, Anne — University of Pittsburgh at Pittsburgh
- Study coordinator: Wondisford, Anne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.